Company: NCEL
Filing Date: 2025-05-16
Form Type: 20-F
Source: 0001213900-25-044868
Chunk: 347

Company: NewcelX Ltd.
Filing Date: 2025-05-16
Form: 20-F
Item: Item 19
Chunk 347
---
                     492,066  
  COMPREHENSIVE LOSS:                                                                                                                                                                                              
  Net loss                                                                                              $                                     ( 1,980,810      $         ( 12,172,029      $         ( 16,495,680  
  Defined pension plan adjustments                                                                                                                266,924                   ( 107,280                     100,948  
  Total comprehensive loss                                                                              $                                     ( 1,713,887      $         ( 12,279,309      $         ( 16,394,732  
  Basic and diluted net loss per common share                                                           $                                          ( 2.63      $              ( 12.75      $              ( 33.52  
  Weighted average common shares used in computing basic and diluted net loss per common share                                                  1,543,283                     954,401                     492,066  

  (i)      Adjusted for the effect of a 1-to-40 reverse share split that  
           was effective September 27, 2024 (See note 2).                 
 ──────────────────────────────────────────────────────────────────────────

The accompanying notes are an integral part of
these consolidated financial statements.

F-6

NLS PHARMACEUTICS LTD. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY (DEFICIT)

FOR THE YEARS ENDED DECEMBER 31, 2024, 2023 AND
2022

 ─────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
  BALANCE, January 1, 2022                                           -              405,585        314,948        42,084,954      ( 41,705,775      ( 151,739           542,388  
  Issuance of common shares direct offering, net                                    75,384         60,308         1,851,205       -                 -                 1,911,513  
  Issuance of warrants, net                                          -              -              -              2,047,208       -                 -                 2,047,208  
  Issuance of pre-funded warrants, net                               -              -              -              5,348,882       -                 -                 5,348,882  
  Issuance of common shares in At-The-Market (ATM) financing         -              -              440